Escitalopram versus venlafaxine XR in the treatment of depression
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
This article reanalyses and reviews data from the two published randomized clinical trials comparing escitalopram and venlafaxine XR in the treatment of patients with major depressive disorder. The aim was to further compare the efficacy and tolerability of escitalopram and venlafaxine XR and to assess the impact of the two treatments on the patient's quality of life, as well as the benefit/risk of treatment. A total of 243 escitalopram-treated patients and 240 venlafaxine XR-treated patients were included in this analysis. Comparable treatment efficacy was achieved with respect to the prospectively defined primary efficacy endpoint (mean change from baseline in Montgomery Asberg Depression Rating Scale (MADRS) total score at week 8). An analysis of the outcome at the end of study by baseline severity showed that the treatment difference became greater the more severely depressed the patients were at baseline. At the highest permitted doses, in the subgroup of patients who were severely depressed (baseline MADRS > or =30), patients treated with escitalopram had a statistically significantly greater improvement (P<0.05) in mean MADRS total scores than patients treated with venlafaxine XR at endpoint. For these patients, treatment with 20 mg/day escitalopram resulted in a statistically significantly (P<0.05) higher remission rate at week 8 (47%) than treatment with venlafaxine XR (29%). This difference was confirmed by the analysis of the pooled data, which showed that patients in the escitalopram group had a significantly (P<0.05) higher mean number of depression-free days (30.4 days) than those in the venlafaxine XR group (26.2 days) over the 8-week period. The relative benefit of escitalopram versus venlafaxine XR was 1.46, indicating that a patient was more likely to benefit from treatment with escitalopram. The proportions of patients who withdrew owing to adverse events were 7.5% in the escitalopram group and 11.2% in the venlafaxine XR group. The mean number of discontinuation emergent signs and symptoms in the venlafaxine XR group (mean: 5.0) was significantly (P<0.001) higher than for the escitalopram group (mean: 2.4).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Functioning and Well-being of Depressed Patients: Results From the Medical Outcomes Study
Wells, K. B. (1989) · JAMA · doi:10.1001/jama.1989.03430070062031 · Cited by 2,130
Evidence of the dual mechanisms of action of venlafaxine
Harvey, A. T., Rudolph, R. L., & Preskorn, S. H. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.5.503 · Cited by 302 · cited 1×
“The superior efficacy of venlafaxine compared with conventional SSRIs is attributed to action on both serotonin and noradrenaline reuptake, and this action becomes relevant in terms of efficacy only at higher doses (Harvey et al., 2000).”
BackgroundPeretti, S., Judge, R., & Hindmarch, I. (2000) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2000.tb10944.x · Cited by 236
Bielski, R. J., Ventura, D., & Chang, C.-C. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0906 · Cited by 178 · cited 18×
“In the study by Bielski et al. (2004), patient functioning was assessed by the Center for Epidemiological Studies-Depression Copyright © Lippincott Williams & Wilkins.”
BackgroundMethodResultInfluentialMontgomery, S. A., Huusom, A. K. T., & Bothmer, J. (2004) · Neuropsychobiology · doi:10.1159/000078225 · Cited by 168
Self-citationLader, M., Stender, K., Bürger, V., & Nil, R. (2004) · Depression and Anxiety · doi:10.1002/da.20014 · Cited by 163 · cited 1×
“, 2005), in social anxiety disorder (Lader et al., 2004; Stein et al., 2006) and in generalized anxiety disorder (Baldwin et al.”
BackgroundOnset of action of escitalopram compared with other antidepressants: results of a pooled analysis
Kasper, S., Spadone, C., Verpillat, P., & Angst, J. (2006) · International Clinical Psychopharmacology · doi:10.1097/01.yic.0000194375.42589.c3 · Cited by 100
Third-Generation Antidepressants: Do They Offer Advantages Over the SSRIs?
Olver, J. S., Burrows, G. D., & Norman, T. R. (2001) · CNS Drugs · doi:10.2165/00023210-200115120-00004 · Cited by 63
Abdelmawla, Langley, Szabadi, & Bradshaw (1999) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1999.00031.x · Cited by 58 · cited 1×
“Although there is some evidence of noradrenergic effects on papillary and vasoconstriction measures at lower doses (Abdelmawla et al., 1999; Bitsios et al., 1999), the superiority of venlafaxine over conventional SSRIs has only been shown in those studies that used high doses of venlafaxine in either the IR or XR form…”
Background
Cited by
Wolff, A., Joshi, R. K., Ekström, J., Aframian, D., Pedersen, A. M. L., Proctor, G., Narayana, N., Villa, A., Sia, Y. W., Aliko, A., et al. (2017) · Drugs in R&D · doi:10.1007/s40268-016-0153-9 · Cited by 364
Papakostas, G. I., Fava, M., & Thase, M. E. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.08.010 · Cited by 284
Montgomery, S. A., & Möller, H.-J. (2009) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e32832a8eb2 · Cited by 121
Self-citationAntidepressant Withdrawal and Rebound Phenomena
Henssler, J., Heinz, A., Brandt, L., & Bschor, T. (2019) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2019.0355 · Cited by 50
Escitalopram: A Review of its Use in the Management of Anxiety Disorders
Dhillon, S., Scott, L. J., & Plosker, G. L. (2006) · CNS Drugs · doi:10.2165/00023210-200620090-00010 · Cited by 47
Metadata
- Authors
- Montgomery, S. A., & Andersen, H. F.
- Venue
- International Clinical Psychopharmacology
- Published
- 2006-09
- Volume
- 21
- Issue
- 5
- Pages
- 297-309
- ISSN
- 0268-1315 (ISSN-L)
- OpenAlex
- W1994418303
- Cited by
- 59
- References
- 9
- FWCI
- 4.91
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Escitalopram versus venlafaxine XR in the treatment of depression. https://app.cochat.ai/papers/10.1097/00004850-200609000-00008
- The paper
- Montgomery, S. A., & Andersen, H. F. (2006). Escitalopram versus venlafaxine XR in the treatment of depression. International Clinical Psychopharmacology. https://doi.org/10.1097/00004850-200609000-00008
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.